Skip to main content
SpringerLink
Log in

Prognostic value of procalcitonin in Legionella pneumonia

  • Article
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

The diagnostic reliability and prognostic implications of procalcitonin (PCT) (ng/ml) on admission in patients with community-acquired pneumonia (CAP) due to Legionella pneumophila are unknown. We retrospectively analysed PCT values in 29 patients with microbiologically proven Legionella-CAP admitted to the University Hospital Basel, Switzerland, between 2002 and 2007 and compared them to other markers of infection, namely, C-reactive protein (CRP) (mg/l) and leukocyte count (109/l), and two prognostic severity assessment scores (PSI and CURB65). Laboratory analysis demonstrated that PCT values on admission were >0.1 in over 93%, >0.25 in over 86%, and >0.5 in over 82% of patients with Legionella-CAP. Patients with adverse medical outcomes (59%, n = 17) including need for ICU admission (55%, n = 16) and/or inhospital mortality (14%, n = 4) had significantly higher median PCT values on admission (4.27 [IQR 2.46–9.48] vs 0.97 [IQR 0.29–2.44], p = 0.01), while the PSI (124 [IQR 81–147] vs 94 [IQR 75–116], p = 0.19), the CURB65 (2 [IQR 1–2] vs 1 [1–3], p = 0.47), CRP values (282 [IQR 218–343], p = 0.28 vs 201 [IQR 147–279], p = 0.28), and leukocyte counts (12 [IQR 10–21] vs 12 [IQR 9–15], p = 0.58) were similar. In receiver operating curves, PCT concentrations on admission had a higher prognostic accuracy to predict adverse outcomes (AUC 0.78 [95%CI 0.61–96]) as compared to the PSI (0.64 [95%CI 0.43–0.86], p = 0.23), the CURB65 (0.58 [95%CI 0.36–0.79], p = 0.21), CRP (0.61 [95%CI 0.39–0.84], p = 0.19), and leukocyte count (0.57 [95%CI 0.35–0.78], p = 0.12). Kaplan-Meier curves demonstrated that patients with initial PCT values above the optimal cut-off of 1.5 had a significantly higher risk of death and/or ICU admission (log rank p = 0.003) during the hospital stay. In patients with CAP due to Legionella, PCT levels on admission might be an interesting predictor for adverse medical outcomes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Muller B, Harbarth S, Stolz D, Bingisser R, Mueller C, Leuppi J et al (2007) Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 7:10. doi:10.1186/1471-2334-7-10

    Article  PubMed  Google Scholar 

  2. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39(2):206–217. doi:10.1086/421997

    Article  PubMed  CAS  Google Scholar 

  3. Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363(9409):600–607. doi:10.1016/S0140-6736(04)15591-8

    Article  PubMed  CAS  Google Scholar 

  4. Briel M, Christ-Crain M, Young J, Schuetz P, Huber P, Periat P et al (2005) Procalcitonin-guided antibiotic use versus a standard approach for acute respiratory tract infections in primary care: study protocol for a randomised controlled trial and baseline characteristics of participating general practitioners. BMC Fam Pract 6:34. doi:10.1186/1471-2296-6-34

    Article  PubMed  Google Scholar 

  5. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, Huber PR et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 174(1):84–93. doi:10.1164/rccm.200512-1922OC

    Article  PubMed  CAS  Google Scholar 

  6. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C et al (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131(1):9–19. doi:10.1378/chest.06-1500

    Article  PubMed  CAS  Google Scholar 

  7. Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M (2006) Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 34(10):2596–2602. doi:10.1097/01.CCM.0000239116.01855.61

    Article  PubMed  CAS  Google Scholar 

  8. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE et al (2001) Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 164(3):396–402

    PubMed  CAS  Google Scholar 

  9. Masia M, Gutierrez F, Padilla S, Soldan B, Mirete C, Shum C et al (2007) Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 13(2):153–161. doi:10.1111/j.1469-0691.2006.01629.x

    Article  PubMed  CAS  Google Scholar 

  10. Korppi M, Remes S, Heiskanen-Kosma T (2003) Serum procalcitonin concentrations in bacterial pneumonia in children: a negative result in primary healthcare settings. Pediatr Pulmonol 35(1):56–61. doi:10.1002/ppul.10201

    Article  PubMed  Google Scholar 

  11. Franzin L, Cabodi D (2005) Legionella pneumonia and serum procalcitonin. Curr Microbiol 50(1):43–46. doi:10.1007/s00284-004-4360-1

    Article  PubMed  CAS  Google Scholar 

  12. Prat C, Dominguez J, Andreo F, Blanco S, Pallares A, Cuchillo F et al (2006) Procalcitonin and neopterin correlation with aetiology and severity of pneumonia. J Infect 52(3):169–177. doi:10.1016/j.jinf.2005.05.019

    Article  PubMed  Google Scholar 

  13. Stout JE, Yu VL (1997) Legionellosis. N Engl J Med 337(10):682–687. doi:10.1056/NEJM199709043371006

    Article  PubMed  CAS  Google Scholar 

  14. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58(5):377–382. doi:10.1136/thorax.58.5.377

    Article  PubMed  CAS  Google Scholar 

  15. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE et al (1997) A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336(4):243–250. doi:10.1056/NEJM199701233360402

    Article  PubMed  CAS  Google Scholar 

  16. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ et al (1996) Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 51(10):1010–1016

    Article  PubMed  CAS  Google Scholar 

  17. Woodhead M, Blasi F, Ewig S, Huchon G, Leven M, Ortqvist A et al (2005) Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26(6):1138–1180. doi:10.1183/09031936.05.00055705

    Article  PubMed  CAS  Google Scholar 

  18. Dominguez JA, Gali N, Pedroso P, Fargas A, Padilla E, Manterola JM et al (1998) Comparison of the Binax Legionella urinary antigen enzyme immunoassay (EIA) with the Biotest Legionella Urin antigen EIA for detection of Legionella antigen in both concentrated and nonconcentrated urine samples. J Clin Microbiol 36(9):2718–2722

    PubMed  CAS  Google Scholar 

  19. Lee TC, Vickers RM, Yu VL, Wagener MM (1993) Growth of 28 Legionella species on selective culture media: a comparative study. J Clin Microbiol 31(10):2764–2768

    PubMed  CAS  Google Scholar 

  20. Schuetz P, Christ-Crain M, Wolbers M, Schild U, Thomann R, Falconnier C et al (2007) Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial. BMC Health Serv Res 7:102. doi:10.1186/1472-6963-7-102

    Article  PubMed  CAS  Google Scholar 

  21. Schuetz P, Christ-Crain M, Muller B (2007) Biomarkers to improve diagnostic and prognostic accuracy in systemic infections. Curr Opin Crit Care 13(5):578–585. doi:10.1097/MCC.0b013e3282c9ac2a

    Article  PubMed  Google Scholar 

  22. Nylen ES, Muller B, Becker KL, Snyder RH (2003) The future diagnostic role of procalcitonin levels: the need for improved sensitivity. Clin Infect Dis 36:823–824. doi:10.1086/368088

    Article  PubMed  Google Scholar 

  23. Tang BM, Eslick GD, Craig JC, McLean AS (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7(3):210–217. doi:10.1016/S1473-3099(07)70052-X

    Article  PubMed  CAS  Google Scholar 

  24. Muller B, Christ-Crain M, Schuetz P (2007) Meta-analysis of procalcitonin for sepsis detection. Lancet Infect Dis 7(8):498–499, author reply 502–3. doi:10.1016/S1473-3099(07)70163-9

    Article  PubMed  Google Scholar 

Download references

Competing interests

Authors PS, MCC and BM received support from BRAHMS to attend meetings and fulfilled speaking engagements. BM has served as a consultant and received research support to attend meetings and for travel expenses. All other co-authors declare that they have no competing interests.

Authors’ contributions

Authors PS, JH, RZ, RF, MCC, and BM had the idea for the study and directed the study design, data collection, and analysis and writing of the report. Authors RF, IS, and AT each had substantial contributions in planning of the study, data collection, interpretation of data, and/or writing of the manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University Hospital Basel, Basel, Switzerland

    J. Haeuptle, R. Zaborsky, R. Fiumefreddo, M. Christ-Crain, B. Müller & P. Schuetz

  2. Division of Infectious Diseases, University Hospital Basel, Basel, Switzerland

    A. Trampuz

  3. Institute of Medical Microbiology, University of Basel, Basel, Switzerland

    I. Steffen

  4. Department of Internal Medicine, Kantonsspital Aarau, Tellstrasse, 5001, Aarau, Switzerland

    B. Müller

  5. Microbiology Laboratory, University Hospital Basel, Basel, Switzerland

    R. Frei

Authors
  1. J. Haeuptle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Zaborsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Fiumefreddo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Trampuz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I. Steffen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R. Frei
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Christ-Crain
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. B. Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P. Schuetz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Müller.

Additional information

Jeannine Haeuptle, Roya Zaborsky, and Rico Fiumefreddo contributed equally to this article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haeuptle, J., Zaborsky, R., Fiumefreddo, R. et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 28, 55–60 (2009). https://doi.org/10.1007/s10096-008-0592-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-008-0592-5

Keywords

Search

Navigation